Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645556 | 0.85 | CES1 (0.48) | CES1SRCTDP1L3MBTL1PGR | |
| SCHEMBL9850554 | 0.83 | SRC (0.47) | CES1SRCTDP1L3MBTL1PGR | |
| SCHEMBL28358545 | 0.83 | CES1 (0.50) | CES1SRCTDP1L3MBTL1PGR | |
| SCHEMBL8463346 | 0.83 | CES1 (0.50) | CES1SRCTDP1L3MBTL1PGR | |
| SCHEMBL6699073 | 0.83 | CES1 (0.50) | CES1SRCTDP1L3MBTL1PGR | |
| SCHEMBL3003271 | 0.80 | CES1 (0.52) | CES1SRCTDP1L3MBTL1PGR | |
| SCHEMBL23571738 | 0.79 | HDAC1 (0.52) | TDP1LMNAMAPTSMN1; SMN2TSHR | |
| SCHEMBL28567881 | 0.79 | CES1 (0.52) | CES1SRCTDP1L3MBTL1LMNA | |
| SCHEMBL10493250 | 0.79 | CYP1A2 (0.48) | CES1SRCTDP1L3MBTL1KCNH2 | |
| SCHEMBL27384600 | 0.78 | CES1 (0.50) | CES1SRCTDP1L3MBTL1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3697878-B1 | USE OF ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | S H KELKAR AND COMPANY LTD (IN) | 2026-01-28 | — | — | EP | claimed |
| US-20210207059-A1 | ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | S H KELKAR & COMPANY LIMITED (IN) | 2021-07-08 | — | — | US | claimed |
| EP-3697878-B1 | USE OF ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | S H KELKAR AND COMPANY LTD (IN) | 2026-01-28 | — | — | EP | disclosed |
| US-11549079-B2 | Odorants and compositions comprising odorants | S H KELKAR & COMPANY LIMITED | 2023-01-10 | — | — | US | disclosed |
| US-11549079-B2 | Odorants and compositions comprising odorants | S H KELKAR & COMPANY LIMITED | 2023-01-10 | — | — | US | disclosed |
| US-11447715-B2 | Odorants and compositions comprising odorants | S H KELKAR & COMPANY LIMITED | 2022-09-20 | — | — | US | disclosed |
| US-20210207059-A1 | ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | S H KELKAR & COMPANY LIMITED (IN) | 2021-07-08 | — | — | US | disclosed |
| US-20210207059-A1 | ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | S H KELKAR & COMPANY LIMITED (IN) | 2021-07-08 | — | — | US | disclosed |
| US-20200299611-A1 | ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | S H KELKAR & COMPANY LIMITED (IN) | 2020-09-24 | — | — | US | disclosed |
| US-20200299611-A1 | ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | S H KELKAR & COMPANY LIMITED (IN) | 2020-09-24 | — | — | US | disclosed |
| WO-2019076933-A1 | ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | S H KELKAR & COMPANY LIMITED (IN) | 2019-04-25 | — | — | WO | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-6469041-B2 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-10-22 | — | — | US | disclosed |
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | NEUROGEN CORPORATION | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210207059-A1 | ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | DEK, OR10J3, THOC2 | CES1 3123/4885SRC 4665/4885TDP1 3576/4885 |
| US-20200299611-A1 | ODORANTS AND COMPOSITIONS COMPRISING ODORANTS | DEK, CAT, TAS2R41 | CES1 1806/4885SRC 4407/4885TDP1 3084/4885 |
| US-11549079-B2 | Odorants and compositions comprising odorants | DEK, CAT, TAS2R41 | CES1 1806/4885SRC 4407/4885TDP1 3084/4885 |
| US-11447715-B2 | Odorants and compositions comprising odorants | DEK, OR10J3, THOC2 | CES1 3123/4885SRC 4665/4885TDP1 3576/4885 |
| US-20020042422-A1 | Certain pyrazole derivatives as corticotropin-releasing factor CRF1 ligands | CRH, CRHR1, CRHR2 | CES1 1891/4885SRC 1349/4885TDP1 3072/4885 |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | CES1 2224/4885SRC 2520/4885TDP1 4109/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CES1 1672/4885SRC 2894/4885TDP1 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.